WhiteLab Genomics Raises $10 Million for AI Gene Therapy Development Platform

September 15, 2022

WhiteLab Genomics, a biotech headquartered in France, has received new funding to tune of $10 Million in support of its artificial intelligence (AI) offerings for cell and gene therapy development. The company helps streamline the costly process of early development by using AI to predict treatment effects and prices. The AI is trained on data from several public and private datasets.

According to David  Del Bourgo, “Gene and cell therapies still suffer from poor efficacy, immunological secondary effects and very high development cost. We provide customers with exhaustive predictive models combining genetics and computational biology in order to design and select the top candidates to be tested in the lab. ”

To read more, click here.

Share This Story!